TNFAIP8 (TNF Alpha Induced Protein 8), also known as SCC-S2 (Squamous Cell Carcinoma Antigen 2), is a multifaceted protein that plays critical roles in apoptosis regulation, cell survival, and cancer progression [1]. Initially discovered as a tumor-associated antigen in squamous cell carcinoma, TNFAIP8 has emerged as an important regulator of cell death pathways and inflammatory responses.
The TNFAIP8 gene encodes a 198-amino acid protein that localizes primarily to the cytoplasm, where it functions as a regulator of programmed cell death and cellular stress responses [2]. The protein contains multiple functional domains that enable it to interact with various signaling molecules and modulate key cellular processes.
Located on chromosome 5q23.2, the TNFAIP8 gene is expressed in most tissues, with particularly high expression in hematopoietic cells and various tumors [3]. In the central nervous system, TNFAIP8 is expressed in neurons, astrocytes, and microglia, where it contributes to neuroinflammation and may play roles in neurodegenerative diseases.
| TNF Alpha Induced Protein 8 | |
|---|---|
| Gene Symbol | TNFAIP8 |
| Full Name | TNF alpha induced protein 8 (SCC-S2) |
| Chromosome | 5q23.2 |
| NCBI Gene ID | [25817](https://www.ncbi.nlm.nih.gov/gene/25817) |
| OMIM | 607314 |
| Ensembl ID | ENSG00000116329 |
| UniProt ID | [Q8WXB1](https://www.uniprot.org/uniprot/Q8WXB1) |
| Protein Class | Tumor suppressor, Apoptosis regulator |
| Aliases | SCC-S2, SCC2, TNFAIP8 |
| Associated Diseases | Cancer, Parkinson's Disease, Neuroinflammation, Glioma |
The TNFAIP8 gene spans approximately 5 kb on chromosome 5q23.2 and consists of 5 exons [4]. The gene promoter contains multiple regulatory elements, including:
TNFAIP8 possesses a modular architecture with distinct functional regions:
N-terminus (1-70 aa) Middle (71-140 aa) C-terminus (141-198 aa)
┌────────────────────┐ ┌──────────────────┐ ┌────────────────────┐
│ DED domain │ │ Protein binding │ │ DED domain │
│ (Death effector │ │ region │ │ (Death effector │
│ domain) │ │ │ │ domain) │
│ │ │ Phosphorylation │ │ │
│ TNF-α induced │ │ sites │ │ Apoptosis │
│ │ │ │ │ modulation │
└────────────────────┘ └──────────────────┘ └────────────────────┘
Death Effector Domain (DED) — The N-terminal DED domain (amino acids 1-70) is similar to domains found in adaptor proteins like FADD and caspase-8. This domain enables interactions with components of the apoptosis signaling machinery [5].
Central Binding Region — The middle region (amino acids 71-140) mediates protein-protein interactions and contains phosphorylation sites that regulate TNFAIP8 function.
C-terminal DED Domain — The C-terminal region (amino acids 141-198) contains another DED-like domain that may contribute to apoptosis regulation.
TNFAIP8 undergoes specific post-translational modifications [6]:
TNFAIP8 functions as a key regulator of programmed cell death [7]:
The duality of TNFAIP8's apoptosis regulation makes it a critical node in cellular decision-making between survival and death.
TNFAIP8 regulates autophagy, another form of programmed cell death [8]:
This autophagy regulation connects TNFAIP8 to cellular quality control and survival mechanisms.
TNFAIP8 modulates NF-κB signaling through multiple mechanisms [9]:
This regulatory function links TNFAIP8 to inflammatory responses and cancer progression.
TNFAIP8 influences cell cycle progression [10]:
These functions contribute to TNFAIP8's tumor suppressor activity.
TNFAIP8 exhibits broad but regulated expression [11]:
| Tissue | Expression Level | Notes |
|---|---|---|
| Brain | Moderate | Neurons and glia |
| Lung | High | Epithelial cells |
| Liver | Moderate | Hepatocytes |
| Kidney | Moderate | Tubular cells |
| Immune cells | High | Activated cells |
| Skin | High | Epidermal cells |
Within the central nervous system [12]:
TNFAIP8 expression is controlled at multiple levels [13]:
TNFAIP8 plays important roles in dopaminergic neuron survival [14]:
Dopaminergic Neuron Protection:
Neuroinflammation Control:
In brain tumors [15]:
In neuroinflammatory conditions [16]:
Emerging evidence links TNFAIP8 to AD [17]:
TNFAIP8 interacts with multiple protein partners [18]:
Direct Partners:
Functional Partners:
TNFAIP8 interfaces with multiple signaling cascades [19]:
Tnfaip8-deficient mice have provided important insights [20]:
Overexpression studies show [21]:
RNAi-mediated knockdown demonstrates [22]:
TNFAIP8 genetic variants have been associated with [23]:
| Variant Type | Effect | Disease Association |
|---|---|---|
| Missense | Altered function | Variable |
| Promoter variants | Altered expression | Cancer risk |
| 3' UTR variants | Altered mRNA stability | Modified risk |
Several approaches to modulate TNFAIP8 for therapeutic benefit are under investigation [24]:
| Approach | Mechanism | Status |
|---|---|---|
| RNA interference | Knockdown expression | Preclinical |
| Small molecules | Inhibit TNFAIP8 | Discovery |
| Gene therapy | Modulate expression | Early research |
| Combination therapy | Synergistic approaches | Early research |
Therapeutic targeting of TNFAIP8 faces significant challenges [25]:
TNFAIP8 as a therapeutic target [26]:
| Feature | TNFAIP8 (SCC-S2) | TNFAIP3 (A20) | TNFAIP6 (TSG-6) |
|---|---|---|---|
| Function | Apoptosis regulator | DUB + E3 ligase | HA binding |
| Localization | Cytoplasmic | Cytoplasmic | Extracellular |
| Primary role | Cell death | Inflammation | Matrix remodeling |
| Cancer | Oncogenic | Variable | Unknown |
TNFAIP8 expression analysis may be useful for [27]:
No current clinical trials specifically targeting TNFAIP8, but:
TNFAIP8/SCC-S2 represents a complex regulator of apoptosis, autophagy, and cell proliferation with important roles in both cancer and neuroprotection. Its bidirectional functions make it a challenging but potentially valuable therapeutic target. Understanding TNFAIP8's context-specific actions offers opportunities for developing novel treatments for cancer and neurodegenerative diseases.